The Anti-Inflammatory Effects of Statin in 5/6 Nephrectomized Rats.
- Author:
Moo Yong PARK
1
;
Soo Jung CHOI
;
Jin Kook KIM
;
Seung Duk HWANG
Author Information
1. Department of Internal Medicine, Soonchunhyang University College of Medicine, Bucheon, Korea. sd7hwang@schmc.ac.kr
- Publication Type:Original Article
- Keywords:
HMG-CoA reductase inhibitor;
Chronic renal failure;
5/6 nephrectomy
- MeSH:
Animals;
Blotting, Western;
Body Weight;
Cholesterol;
Creatinine;
Enzyme-Linked Immunosorbent Assay;
Fluorobenzenes;
Humans;
Hydroxymethylglutaryl-CoA Reductase Inhibitors;
Kidney;
Kidney Failure, Chronic;
Lipoproteins;
Male;
Nephrectomy;
Proteinuria;
Pyrimidines;
Rats;
Rats, Sprague-Dawley;
Renal Insufficiency;
Renal Insufficiency, Chronic;
Sulfonamides;
Rosuvastatin Calcium
- From:Korean Journal of Medicine
2011;81(6):740-750
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND/AIMS: In a previous study, statin therapy reduced proteinuria and ameliorated the progression of chronic kidney disease. However, in patients with chronic renal failure (CRF), the beneficial effect of statin therapy on the preservation of renal function has not been determined. Thus, we determined the effect of rosuvastatin on CRF. METHODS: Male Sprague-Dawley rats (6 weeks old) were subjected to 5/6 nephrectomy. Six weeks after the procedure, the rats were divided into control and rosuvastatin-treated groups. Body weight and blood/urine biochemical parameters were measured 6 weeks after 5/6 nephrectomy and 8 weeks after the start of rosuvastatin treatment. Remnant kidneys were harvested at 6 (n = 4) and 14 (n = 8) weeks after 5/6 nephrectomy. RESULTS: During rosuvastatin treatment, changes in body weight and serum total and low-density lipoprotein cholesterol did not differ significantly between the control and rosuvastatin-treated groups. Although serum creatinine and proteinuria increased in both groups, the differences were not significant (p = 0.24 and 0.77, respectively). Immunohistochemical staining, enzyme-linked immunosorbent assays, and western blotting showed that the expression of transforming growth factor-beta1 and intracellular adhesion molecule-1 were reduced in the rosuvastatin-treated group. CONCLUSIONS: Long-term statin treatment may attenuate the inflammatory process in the progression of renal failure.
